Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.67 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.46 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.41 |
| ▸ | LCAT | P04180 | 1/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344799 | 0.88 | PDE10A (0.55) | PDE10AAKR1C3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL26077359 | 0.84 | PDE10A (0.51) | PDE10AAKR1C3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL13059662 | 0.84 | PDE10A (0.51) | PDE10AAKR1C3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL21812386 | 0.84 | PDE10A (0.60) | PDE10AAKR1C3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL578596 | 0.82 | AKR1C3 (0.51) | PDE10AAKR1C3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL345209 | 0.82 | PDE10A (0.49) | PDE10AAKR1C3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL7705886 | 0.82 | PDE10A (1.00) | PDE10A | |
| SCHEMBL24735175 | 0.81 | PDE10A (0.48) | PDE10ADEGS1PDE2APDE1BPDE4D | |
| SCHEMBL23172319 | 0.81 | PDE10A (0.48) | PDE10AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL15034209 | 0.81 | PDE10A (0.67) | PDE10AGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12636385-B2 | Selective ligands for tau aggregates | SENTONIX, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12600732-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4570320-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| EP-4069237-B1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| CN-117916231-A | Compounds for inhibiting or degrading target proteins, compositions comprising the same, methods of making and methods of using the same | 纽力克斯治疗公司 | 2024-04-19 | — | — | CN | disclosed |
| EP-4334302-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4334303-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | Nurix Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117693502-A | Compounds for inhibiting or degrading ITK, compositions comprising the same, methods of making the same, and methods of using the same | 纽力克斯治疗公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| CN-103687855-A | Imidazole derivatives | INTERVET INT BV | 2014-03-26 | — | — | CN | disclosed |
| US-8604023-B2 | 1,4-benzodiazepinone compounds and their use in treating cancer | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-12-10 | — | — | US | disclosed |
| WO-2012164071-A1 | IMIDAZOLE DERIVATIVES | INTERVET INTERNATIONAL B.V. (NL) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012164071-A1 | IMIDAZOLE DERIVATIVES | INTERVET INTERNATIONAL B.V. (NL) | 2012-12-06 | — | — | WO | disclosed |
| US-20120094982-A1 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094982-A1 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094982-A1 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010132580-A2 | METHODS OF INHIBITING THE GHRELIN/GROWTH HORMONE SECRETATOGUE RECEPTOR PATHWAY AND USES THEREOF | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010121164-A2 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010121164-A2 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636385-B2 | Selective ligands for tau aggregates | MAPT, PSEN2, PSEN1 | PDE10A 1613/4885AKR1C3 2858/4885GRIN2D 314/4885 |
| US-20240279202-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE | ITK, NFATC1, TNIK | PDE10A 3485/4885AKR1C3 1804/4885GRIN2D 4227/4885 |
| US-20120094982-A1 | 1,4-BENZODIAZEPINONE COMPOUNDS AND THEIR USE IN TREATING CANCER | HTR4, HTR1A, HTR3B | PDE10A 2146/4885AKR1C3 882/4885GRIN2D 161/4885 |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | PDE10A 3954/4885AKR1C3 3510/4885GRIN2D 4844/4885 |
| US-12600732-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, BCL9, BCL9L | PDE10A 2473/4885AKR1C3 4479/4885GRIN2D 4614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.